×
Welcome Upcoming Events Virtual Cath Lab Training & Education Future Technology Resources Daily Highlights

Welcome to the
Abiomed 2020
Virtual TCT Booth

Learn how Impella Enables Improved Outcomes for High-Risk PCI, Cardiogenic Shock and Right Heart Failure Patients.


14-18 October 2020

e-Satellites

Sessions of Interest

Events
e-Satellite

PROTECTED PCI IN COVID-19 ERA: THE RISE IN IMPORTANCE OF COMPLETE REVASCULARIZATION

Chair: Cindy Grines, MD
SATURDAY 2:00 PM ET 17 Oct 2020
e-Satellite

ACHIEVING > 70% AMI-CS SURVIVAL: BEST PRACTICES FROM AROUND THE WORLD

Chair: Bill O’Neill, MD
SUNDAY 10:00 AM ET 18 Oct 2020
Abstracts
Best of Abstracts

Safety and Efficacy of Percutaneous MCS During HR-PCI Using Contemporary Practices: Results From the Largest Single Prospective Real-world Study (PROTECT III)

Presenter: Bill O'Neill, MD
THURSDAY 3:24 PM ET 15 Oct 2020
Abstract

Intermediate-Term Left Ventricular Function Following Non-Emergent Impella Protected PCI: RESTORE EF Study

Presenter: Mitul Patel, MD
WEDNESDAY 14 Oct 2020
Click Here To Watch

Social Media

Live Updates

Twitter Feed

Undertreated Patient Population for High-Risk PCI

Last year over 300,000 of surgical turned down patients with CAD were not treated with PCI.1 This patient population is often undertreated due to the high-risk factors and co-morbidities. The SCAI consensus has recently endorsed the importance and the benefits of complete revascularization for patients with complex CAD. This study shows increased benefits for high-risk patients.

Current Clinical Data

Seth Bilazarian, MD reviews Impella Heart Pump Data from interim Protect III and USpella available prior to TCT Connect 2020. Results from Protect III study will be presented as Best of Abstracts on Oct 15th.

Contemporary Protected PCI Data

Jeffrey Moses, MD discusses Contemporary Practices of HR-PCI Using Percutaneous MCS: Results from PROTECT III.

OCT 16, 2020

Protected PCI in Covid-19 Era

Watch Cindy Grines, MD, FACC, MSCAI discuss The Rise in Importance of Complete Revascularization.

OCT 14,2020

Impact of Revascularization Extent

Watch Francesco Burzotta, MD review the Clinical Impact Of Revascularization Extent In Protected PCI.

OCT 14, 2020

Best Practices and Improved Outcomes in Cardiogenic Shock

IN AMI-CS the mortality rate has been approximately 50% for decades. Recent studies (NCSI2, INOVA3 and J-PVAD4) have shown that utilizing best practices with patients in cardiogenic shock have led to demonstrated survival rates of > 70%. Early patient identification with early Impella support, along with the avoidance of inotropes, are just some of the best practices that can lead to improved patient outcomes.

Best Practice Protocols

Bill O'Neill on the Achieving >70% AMI-CS Survival Insights from National Cardiogenic Shock Initiative.

OCT 14, 2020

Insight From Japan

Junya Ako, MD provides Insight from J-PVAD STudy: The Efficacy and Safety of ALL Impella Use in Japanese Patients with Drug-Resistant Acute Heart Failure.

OCT 14, 2020

Importance of Timing

Giuseppe Tarantini, MD, PhD, FESC highlights the Importance of Timing and Impact of Extensive Revascularization on Long-term Survival.

OCT 14, 2020

The Science of Unloading

Navin Kapur, MD, FAHA, FACC, FSCAI discusses Ventricular Unloading.

Future Technology

Advancing The Field of Heart Recovery

Dave Weber, PhD. shares the future of Abiomed's technology for the future of heart recovery. Here you will learn about the Impella 5.5 with SmartAssist and future technologies designed to be SMALL, SMART, and CONNECTED.

 

Additional Resources

To Learn More About Abiomed and The Impella Heart Pump, Use The Links Below

CAMP PCI

CAMP PCI (Coronary Artery & Myocardial Protected PCI) is dedicated to improving patient outcomes and quality of life with supported high-risk PCI by utilizing best practices, techniques and technologies to enable safer, more effective and complete revascularization.

FIND OUT MORE

Refererences - 1. Doshi D, et al. J Am Coll Cardiol. 2016;68(5):450-458 2. Basir, M., et al. (2019). Catheter Cardiovasc Interv, 93(7), 1173-1183 3.Tehrani, B., et al. (2019). J Am Coll Cardiol, 73(13), 1659–1669 4. Sawa, Y. (2020). Japanese Circulation Society, Kyoto

IMP-1728